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Choline PET based dose-painting in prostate







Background: Several randomized trials have documented the value of radiation dose escalation in patients with
prostate cancer, especially in patients with intermediate risk profile. Up to now dose escalation is usually applied to
the whole prostate. IMRT and related techniques currently allow for dose escalation in sub-volumes of the organ.
However, the sensitivity of the imaging modality and the fact that small islands of cancer are often dispersed
within the whole organ may limit these approaches with regard to a clear clinical benefit. In order to assess
potential effects of a dose escalation in certain sub-volumes based on choline PET imaging a mathematical dose-
response model was developed.
Methods: Based on different assumptions for a/b, g50, sensitivity and specificity of choline PET, the influence of
the whole prostate and simultaneous integrated boost (SIB) dose on tumor control probability (TCP) was
calculated. Based on the given heterogeneity of all potential variables certain representative permutations of the
parameters were chosen and, subsequently, the influence on TCP was assessed.
Results: Using schedules with 74 Gy within the whole prostate and a SIB dose of 90 Gy the TCP increase ranged
from 23.1% (high detection rate of choline PET, low whole prostate dose, high g50/ASTRO definition for tumor
control) to 1.4% TCP gain (low sensitivity of PET, high whole prostate dose, CN + 2 definition for tumor control) or
even 0% in selected cases. The corresponding initial TCP values without integrated boost ranged from 67.3% to
100%. According to a large data set of intermediate-risk prostate cancer patients the resulting TCP gains ranged
from 22.2% to 10.1% (ASTRO definition) or from 13.2% to 6.0% (CN + 2 definition).
Discussion: Although a simplified mathematical model was employed, the presented model allows for an
estimation in how far given schedules are relevant for clinical practice. However, the benefit of a SIB based on
choline PET seems less than intuitively expected. Only under the assumption of high detection rates and low initial
TCP values the TCP gain has been shown to be relevant.
Conclusions: Based on the employed assumptions, specific dose escalation to choline PET positive areas within
the prostate may increase the local control rates. Due to the lack of exact PET sensitivity and prostate a/b
parameter, no firm conclusions can be made. Small variations may completely abrogate the clinical benefit of a SIB
based on choline PET imaging.
Introduction
Several randomized trials have documented a clear dose-
response relationship for prostate cancer. Although not
employing modern IMRT techniques the M. D. Ander-
son phase III dose escalation trial was the first rando-
mized trial to prove 78 Gy vs. 70 Gy. It resulted in
better biochemical control for the higher radiation dose
in patients with intermediate-risk features [1]. Other
groups obtained similar results [2-6]. This interpretation
is corroborated by population based approaches showing
that only doses ≥ 72 Gy are associated with adequate
tumor control [7,8].
The implementation of IMRT into clinical practice of
prostate cancer radiation treatment enables the physi-
cian to increase the doses in focal areas of the gland,
which is in contrast to the central dogma in radiation
oncology to strive for a homogeneous dose to the target
volume [9]. However, this approach might have two
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minor part of the target volume and thus, the probabil-
i t yo fs i d ee f f e c t ss h o u l db el owered [10]. Secondly the
biological efficacy may be increased by the use of higher
doses per fraction.
The first who addressed this issue were Pickett, Xia
and colleagues [11,12], later on further studies were
conducted [13,14], also in case of high-risk prostate can-
cer [15]. Li et al. reported a new IMRT simultaneous
integrated boost (SIB) strategy that irradiates prostate
via hypo-fractionation while irradiating pelvic nodes
with the conventional fractionation. Compared to the
conventional two-phase treatment, the proposed SIB
technique offers potential advantages, including better
sparing of critical structures leading to less inconti-
nence, rectal bleeding, irritative symptoms [16-20] or
urethral toxicity [21], more efficient delivery, shorter
treatment duration, and better biological efficacy [22].
Fonteyne et al. reported that addition of an IMRT SIB
to an intra-prostatic lesion (defined by magnetic reso-
nance imaging) did not increase the severity or inci-
dence of acute toxicity [23]. Furthermore new
techniques like volumetric modulated arcs, helical
tomotherapy or IMPT additionally showed improve-
ments in conformal avoidance relative to fixed beam
IMRT [24,25].
Despite the technical advances in radiotherapy the
optimal treatment for prostate cancer strongly depends
on the accuracy of tumor characterization and staging.
Positron emission tomography (PET) is an exquisitely
sensitive molecular imaging technique using positron-
emitting radioisotopes coupled to specific ligands [26].




11C] acetate, have been described for the
detection of prostate cancer. However, larger trials are
still needed to establish their final clinical value con-
cerning the primary detection and the staging of pros-
tate cancer [27].
In principle, signal-generation is based on an increased
choline metabolism in prostate cancer leading to an
increased up-take in tumor tissue compared to that of
benign tissue [28]. However, benign prostate hyperplasia
and inflammatory changes may also lead to increased
uptake thereby lowering the specificity of the PET signal.
A precise volumetric assessment of PET signals is of
rising importance for radiotherapy (RT) planning [29].
The use of choline PET/CT data to detect tumor spots
within the prostate has been analyzed and first clinical
experiences in lymph node-positive patients were
reported [30]. In this regard, Ciernik et al. investigated
the utility of F-18-choline PET signals to serve as a tar-
get for semi-automatic segmentation for forward treat-
ment planning of prostate cancer. F-18-choline PET and
CT scans of ten patients with histologically proven
prostate cancer without extra-capsular tumor extension
were acquired using a combined PET/CT scanner. Plan-
ning target volumes (PTV’s) derived from CT and F-18-
choline PET yielded comparable results. 3D-conformal
planning with CT or F-18-choline PET resulted in com-
parable doses to the rectal wall. Choline PET signals of
the prostate provided adequate spatial information to be
used for standardized PET-based target volume defini-
tion [31].
As PET allows for detection of small lesions within
the prostate and modern IMRT techniques can be used
for integrated focal boosting, it is evident to use PET
information in order to escalate the dose within defined
tumor spots also called biologically guided radiotherapy
[32]. This type of selective dose-escalation has already
been implemented successfully using spectroscopic MRI
data [23,33,34]. Although doing so may be intuitively
reasonable, the true effect of such procedures is strongly
influenced by a multitude of factors. We therefore
attempted to develop a method to estimate the increase
of local tumor control using an IMRT SIB to choline
PET positive hotspots within the gland. The computa-
tions were done in a putative intermediate-risk collective
reflecting the fact that these patients will have the most
benefit by any dose escalation approach.
Methods
The best currently available dataset for dose-response
relationships in prostate cancer was derived from a
study of 235 low-risk and 382 intermediate-risk patients
treated between 1987 and 1998 with external beam RT
alone at the M. D. Anderson Cancer Center [35].
Local control (biochemical no evidence of disease) was
defined in two different ways; Firstly, ASTRO definition
was employed: Time to PSA failure is defined as the end
of RT to the mid-point between the PSA nadir and the
first PSA rise [35]. Secondly, the Houston definition
defines biochemical failure as PSA rise of ≥ 2n g / m l
above the current nadir PSA (CN + 2) [36-38]. In both
settings detectable local, nodal and distant relapses as
well as initiation of hormonal treatment are scored as
failures.
In order to develop a mathematical TCP model for
prostate cancer, we firstly assumed the prostate to be a
geometrical structure subdivided into a fixed number of
voxels (defining their volume as vi = 1). Voxels includ-
ing tumor cells are called tumorlets.
N is defined as the number of clonogenic cells within
the tumor, V as the volume of the target volume and ni
is defined as the density of tumor cells within a tumor-
let. We furthermore assumed that all tumorlets have the
same density of clonogenic cells. In order to achieve this
in practice one has to define the voxels as sufficiently
small.
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Poisson distribution [39]. In such a geometrical setting






SFi is the surviving fraction within the single sub-
volume with the running index i (ranging from 1 to m
=V / v i). Using the well-known linear-quadratic model


















with dj as single dose (usually 1.8 or 2 Gy), n as the
number of fractions and a, b as the parameters from
the linear-quadratic model which refer to the radio-sen-
sitivity of the tumor cells (a represents lethal lesions
made by one-track action and b accounts for lethal
lesions made by two-track action, [40]). In this formula
the tumor doubling time is not considered.
Relevant a/b ratios can be obtained from both in
vitro experiments and clinical fractionation studies and
give the dose where linear and quadratic effect are
equal according to total cell kill [41] whereas in vitro
data do not necessarily predict the radio-sensitivity of
tissues in clinical radiotherapy. There is a wide varia-
tion of a/b values for prostate cancer in the literature
with the exact value of a/b being still unknown
[41-51].
Thus, the following calculations were based on the
values determined by Fowler et al. (a/b =1 . 5G y ,a =
0.04 Gy
-1) [43], Wang et al. (a/b =3 . 1G y ,a =0 . 1 5
Gy
-1 [49,52]) and Valdagni et al. (a/b = 8.3 Gy [46,48]).
Another relevant parameter to describe the TCP is the
slope of the killing curve (g50) which relates to the

















Cheung et al. calculated a g50 value of 2.2 [1.1-3.2,
95% CI] and TCD50 = 67.5 Gy [65.5-69.5 Gy, 95% CI]
(ASTRO definition) or g50 = 1.4 [0.2-2.5, 95% CI] and
TCD50 = 57.8 Gy [49.8-65.9 Gy, 95% CI] (CN + 2 defi-
nition) for intermediate-risk patients [35]. The corre-
sponding TCP curves are shown in Figure 1.
Those voxels not containing a clonogenic cell (pure
prostate tissue) do not contribute to the overall TCP as
the corresponding factor equals 1.
Summarizing all these equations, and after some alge-
braic manipulations keeping in mind that vi =1 ,o n e
obtains:
TCP TCP e SIB conv
SF N / 
 
ΔSF denotes the difference between boosted and con-
ventional surviving fraction (conventional means with-
out boost, but 3D-conformal RT or IMRT technique).
This expression has to be corrected due to the limited
sensitivity in detecting all clonogenic cells. The sensitiv-
i t yv a l u e sf o rc h o l i n eP E Tr a n g ef r o m8 1 %( f o raS U V
of 2.65) [54] down to 73% [28,55] or 64% [56] (Addi-
tional file 1 offers the possibility to specify different
parameters for intermediate-risk prostate cancer to cal-
culate the effect of an IMRT SIB).
This is a simplified picture of reality as the sensitivity
of detecting tumor cells within the prostate is depen-
dent on the size or more precise intensity of the enhan-
cing tumor lesion. Partial volume effects can severely
affect images both qualitatively and quantitatively: For
any hot lesion of a small size and embedded in a colder
background, this effect spreads out the signal. It typi-
cally occurs whenever the tumor size is less than 3
times the full width at half maximum (FWHM) of the
reconstructed image resolution. The maximum value in
the hot tumor then will be lower than the actual maxi-
mum value. A small tumor will look larger but less
aggressive than it actually is [57]. The model assumes
the detection rate for the sake of simplicity size-inde-
pendent and constant, the aforementioned sensitivities
from the literature are taken as best guesses for the
detection rate.
The model used for our calculation is based on a
number of additional assumptions. Thus, several
Figure 1 Tumor control probability curves for both definitions
of local control derived by data of Cheung et al. (RT of the
whole prostate).
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preting the data:
1) The assumption of a homogeneous density of clo-
nogenic tumor-cells is noto b v i o u s .T h e r em a yb e
islands within the prostate with a higher clonogenic
density. However, this is no strict contradiction to
our assumption as the sub-voxels may be scaled
down until only empty voxels and voxels with a
small but uniform number of clonogenic cells
remain left.
2) The given model is incapable of reflecting biologi-
cal sub-volume effects adequately: For example, one
may assume that hypoxic areas within high-density
tumor foci may cause a locally enhanced radio-resis-
tance. Since all values used for our calculation are
b a s e do nw h o l eo r g a nT C P s ,t h eg i v e nm o d e l
ignores issues of focally increased resistance.
3) Biologically, a complex feedback between the
tumor and surrounding normal tissue exists. For
example, the release of certain cytokines after radia-
tion damage may influence the surrounding tumor
tissue and vice versa. Again the given model is not
able to integrate the putative interaction of adjacent
clonogenic tumor and stroma cells.
4) It is assumed that all clonogenic cells within the
tumor have a uniform radiosensitivity.
All these effects may be in place but do not seem to
have much influence in practice. One prominent exam-
ple is the comparison between primary and salvage
radiotherapy.
After prostatectomy with positive surgical margins
adjuvant radiotherapy improves disease-free survival
rates and thus it is discussed as a new standard of adju-
vant treatment in selected cases [58]; in cases of local
relapse, salvage radiotherapy is the only potentially cura-
tive treatment approach [59]. The doses being necessary
to control microscopic tumor seem to be higher than
initially expected and to be similar to those for
macroscopic tumor within the setting of a primary treat-
ment [60].
Results
The relevant parameters fed into our model in order to
calculate the increase in whole organ TCP are: Sensitiv-
ity of choline PET, a, a/b, g50, whole prostate dose, SIB
dose and dose per fraction.
In order to present the calculations different represen-
tative scenarios have been tested:
1. High sensitivity of choline PET, low whole prostate
dose, high g50 (ASTRO consensus), Fowler’s a/b
This parameter set was chosen to calculate a putative
maximum TCP increase: Choline PET sensitivity was set
to 81% and 74 Gy were chosen as homogeneous pros-
tate dose. a/b was set to 1.5 Gy (a =0 . 0 4G y
-1), g50
was chosen according to Cheung’sd a t aw i t ht h e
ASTRO definition. As shown in Figure 1 this parameter
set leads to a higher steepness of the TCP curve. The
results are shown in Table 1. The TCP in this setting
with homogeneous dose of 74 Gy within the prostate
was 67.3% and was improved by 23.1% up to 90.4%
using a SIB.
2. High sensitivity of choline PET, low whole prostate
dose, low g50 (CN + 2 definition), Fowler’s a/b
In contrast, one may assume a parameter set with
slightly less optimal conditions for a SIB. Table 2 sum-
marizes the results when assuming a higher detection
rate for PET (81%), a low homogeneous whole prostate
d o s e( 7 4G y ) ,aS I Bd o s eo f9 0G ya n dr a d i o - s e n s i t i v i t y
parameters as described by Fowler et al. (a/b =1 . 5G y ,
a =0 . 0 4G y
-1)a n dg50 taken again from Cheung’s data
but this time according to the CN + 2 definition. The
calculated TCP without SIB was 96.0% which leaves
only an increase of 2.9% with a SIB.
This result is basically driven by a high initial control
probability. In reality the initial clinical control probabil-
ity is lower [35].
Table 1 TCP-increase for high sensitivity of choline PET, low whole prostate dose, high g50(ASTRO consensus) and
Fowler’s a/b
a [Gy
-1] a/b [Gy] g50 Det. rate PET [%] Dose [Gy] SIB [Gy] Single dose [Gy] TCPconv [%] TCP Increase [%]
0.04 1.5 2.2 81 74 90 2 67.3 23.1
Calculation of the increase in TCP with whole prostate dose of 74 Gy after boosting choline PET positive regions within the prostate up to 90 Gy. a and a/b are
estimated from Fowler’s data and g50 from Cheung’s data (ASTRO definition). For choline PET a high sensitivity was used.
Table 2 TCP-increase for high sensitivity of choline PET, low whole prostate dose, low g50(CN + 2 definition) and
Fowler’s a/b
a [Gy
-1] a/b [Gy] g50 Det. rate PET [%] Dose [Gy] SIB [Gy] Single dose [Gy] TCPconv [%] TCP Increase [%]
0.04 1.5 1.4 81 74 90 2 96.0 2.9
Calculation of the TCP-increase after boosting choline PET positive regions within the prostate up to 90 Gy. a/b is estimated from Fowler’s data and g50 from
Cheung’s data (CN + 2 definition). For choline PET a high sensitivity was used.
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dose, low g50 (CN + 2 definition), Fowler’s a/b
A “worst case” scenario is considered where a low sensi-
tivity of PET is presumed, the homogeneous whole
prostate dose is high (see Table 3, 78 Gy along the dose
concept of the M. D. Anderson trial [1]), a/b is low and
g50 is less steep than the corresponding ASTRO value.
Based on these assumptions the gain of a SIB is low,
as the initial TCP is again very high (97.0%) and as the
remaining SIB effect is small (1.4%). Again, this result is
in contrast to clinical reality reflected in the Cheung
data [35].
4. High sensitivity of choline PET, low whole prostate
dose, g50 arbitrary, Wang’s a/b
Using a/b and a values originally obtained by Wang et
al. one obtains independently of g50 or the whole organ
dose a TCP of 100% which leaves no benefit for a SIB
(Table 4). This result is probably due to the fact that
the respective g50 as well as a/b parameters were
derived from independent clinical trials.
5. Different sensitivities of choline PET, low whole
prostate dose, different a/b values, calculated a, high g50
(ASTRO definition)
In order to circumvent the problem of overestimating
the initial TCP one can try to reproduce the M. D.
Anderson data (Cheung et al.) employing different a/b
values (Fowler, Wang, Valdagni) and fitting an optimal
a value to finally achieve a realistic concordance
between observed TCD50 and calculated TCD50 value.
I nT a b l e5t h eA S T R Oc o n s e n s u sw a su s e df o rt h e
definition of tumor control, leading to a steeper TCP
curve (see Figure 1). Using a low whole prostate dose
(74 Gy), the baseline tumor control was 68.7%. In this
setting the SIB mediated TCP increase was strongly
dependent on the sensitivity of the choline PET. Assum-
ing a sensitivity rate of 81%, the TCP was increased by
22.2%, for 64% the increase was lowered to 17.0%.
Using higher a/b values automatically resulted in a
lower TCP gain. This differ e n c ei sb a s e do nt h ef a c t
that in the given model a was optimized with fixed g50
and a/b, resulting in different TCP curves.
Table 3 TCP-increase for low sensitivity of choline PET, high whole prostate dose, low g50(CN + 2 definition) and
Fowler’s a/b
a [Gy
-1] a/b [Gy] g50 Det. rate PET [%] Dose [Gy] SIB [Gy] Single dose [Gy] TCPconv [%] TCP Increase [%]
0.04 1.5 1.4 64 78 90 2 97.0 1.4
Calculation of the TCP-increase after boosting choline PET positive regions within the prostate up to 90 Gy; the whole organ dose was set to 78 Gy. a/b is
estimated from Fowler’s data and g50 from Cheung’s data (CN + 2 definition). For choline PET a low sensitivity was used.
Table 4 TCP-increase for high sensitivity of choline PET, low whole prostate dose, g50arbitrary and Wang’s a/b
a [Gy
-1] a/b [Gy] g50 Det. rate PET [%] Dose [Gy] SIB [Gy] Single dose [Gy] TCPconv [%] TCP Increase [%]
0.15 3.1 1.4 81 74 90 2 100 0
0.15 3.1 2.2 81 74 90 2 100 0
Calculation of the TCP-increase after boosting choline PET positive regions within the prostate up to 90 Gy. a/b is estimated from Wang’s data and g50 arbitrary.
For choline PET a high sensitivity was assumed.
Table 5 TCP-increase for different sensitivities of choline PET, low whole prostate dose, different a/b values, calculated
a and high g50 (ASTRO definition)
a [Gy
-1] a/b [Gy] g50 Det. rate PET [%] Dose [Gy] SIB [Gy] Single dose [Gy] TCPconv [%] TCP Increase [%]
0.04 1.5 2.2 81 74 90 2 68.7 22.2
0.04 1.5 2.2 64 74 90 2 68.7 17.0
0.06 3.1 2.2 81 74 90 2 68.7 21.4
0.06 3.1 2.2 64 74 90 2 68.7 16.4
0.08 8.3 2.2 81 74 90 2 68.7 20.1
0.08 8.3 2.2 64 74 90 2 68.7 15.4
Calculation of the TCP-increase after boosting choline PET positive regions within the prostate up to 90 Gy. a/b was set to either Fowler’s/Wang’s or Valdagni’s
value, a was analytically determined in order to achieve agreement between calculated TCD50 and TCD50 obtained by Cheung et al. g50 was again taken from
Cheung’s data (ASTRO definition).
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prostate dose, different a/b values, calculated a, high g50
(ASTRO definition)
Compared to Table 5 in Table 6 a higher whole prostate
dose (78 Gy) was used. The initial TCP could be
improved to 77.2%. The increase in TCP by the given
SIB dose was lower ranging from 14.9% (high PET sen-
sitivity, low a/b) to 10.1% (low detection rate, high a/b).
7. Different sensitivities of PET, low whole prostate dose,
different a/b values, calculated a, low g50 (CN + 2
definition)
I nT a b l e7t h eC N+2c o n s e n s u sw a su s e dt od e f i n e
tumor control, leading to less steep TCP curves (see Fig-
u r e1 ) .A g a i n ,al o ww h o l ep r o s t a t ed o s ew a su s e d ;t h e
baseline tumor control then was calculated to be 80.0%.
Similarly to the previous scenario, the TCP-increase by
a given SIB was also strongly related to the assumed
sensitivity of the choline PET. Using a sensitivity of 81%
the TCP was increased by 13.2% compared to 22.2% in
the same setting employing the ASTRO definition. In
contrast, for 64% sensitivity the increase was only 10.3%.
Replacing the given a/b by higher values resulted in
lower TCP gains. The lowest increase for TCP was seen
for Valdagni’s a/b with a low choline PET sensitivity:
9.0%.
8. Different sensitivities of PET, high whole prostate dose,
different a/b values, calculated a, low g50 (CN + 2
definition)
Compared to Table 7 in Table 8 a higher whole prostate
dose was used (78 Gy). The initial TCP could be
improved to 80%. The increase in TCP was lower as it
ranged from 9.1% (high detection rate of PET, low a/b)
to 6.0% (low detection rate, high a/b).
Discussion
Using a simplified mathematical model allowed us to
determine the increase in TCP after an IMRT SIB based
on choline PET positive intra-prostatic lesions. The
model has been based on several fundamental assump-
tions including uniform clonogenic cell density, no
interaction between adjacent tumor cells, no sub-volume
effects and a uniform radio-sensitivity of all tumor cells.
Furthermore the model does not consider population
differences or time factors [61]. This model is substan-
tiated by the fact that doses being needed to control
microscopic tumor in an adjuvant/salvage setting seem
to be almost as high as those used in primary therapy
for macroscopic tumors [60].
It was shown that a SIB mediated increase of the
given TCP is strongly dependent on the sensitivity of
the choline PET, the g50-value with special emphasis on
Table 6 TCP-increase for different sensitivities of choline PET, high whole prostate dose, different a/b values,
calculated a and high g50(ASTRO definition)
a [Gy
-1] a/b [Gy] g50 Det. rate PET [%] Dose [Gy] SIB [Gy] Single dose [Gy] TCPconv [%] TCP Increase [%]
0.04 1.5 2.2 81 78 90 2 77.2 14.9
0.04 1.5 2.2 64 78 90 2 77.2 11.5
0.06 3.1 2.2 81 78 90 2 77.2 14.1
0.06 3.1 2.2 64 78 90 2 77.2 11.0
0.08 8.3 2.2 81 78 90 2 77.2 13.1
0.08 8.3 2.2 64 78 90 2 77.2 10.1
Calculation of the TCP-increase after boosting choline PET positive regions within the prostate up to 90 Gy, higher homogeneous whole prostate dose. a/b was
analytically determined in order to achieve agreement between calculated TCD50 and TCD50 obtained by Cheung et al. g50 was again taken from Cheung’s data
(ASTRO definition).
Table 7 TCP-increase for different sensitivities of PET, low whole prostate dose, different a/b values, calculated a and
low g50(CN + 2 definition)
a [Gy
-1] a/b [Gy] g50 Det. rate PET [%] Dose [Gy] SIB [Gy] Single dose [Gy] TCPconv [%] TCP Increase
[%]
0.03 1.5 1.4 81 74 90 2 80 13.2
0.03 1.5 1.4 64 74 90 2 80 10.3
0.04 3.1 1.4 81 74 90 2 80 12.6
0.04 3.1 1.4 64 74 90 2 80 9.8
0.06 8.3 1.4 81 74 90 2 80 11.6
0.06 8.3 1.4 64 74 90 2 80 9.0
Calculation of the TCP-increase after boosting choline PET positive regions within the prostate up to 90 Gy. a/b was set to either Fowler’s/Wang’s or Valdagni’s
value, a was analytically determined in order to achieve agreement between calculated TCD50 and TCD50 obtained by Cheung et al. g50 was again taken from
Cheung’s data (CN + 2 definition).
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treatment of the whole organ and the a/b values.
We observed a high variation between the outcomes
based on different initial assumptions. A critical limita-
tion is the fact that there is no chance to derive a/b and
a values for the calculation of dose-response relation-
ships from the trial by Cheung et al. (the best data avail-
able to date) since a single fixed fractionation schedule
was applied [35].
In keeping with this several inconsistencies occurred
(Table 5, Table 6, Table 7 and Table 8): the calculated
a values did not fit their counterpart in literature except
for Fowler’s data where the deviation was small. In this
case the dependence on g50 and the detection rate of
choline PET became more important.
On the one hand, g50 depends on the failure defini-
tion and data are different with longer follow-up data,
and at present the confidence interval is still wide as g50
= 2.2 [1.1-3.2, 95% CI] (ASTRO definition) or g50 = 1.4
[0.2-2.5, 95% CI] (CN + 2 definition).
On the other hand, a study from Farsad et al. demon-
s t r a t e dt h a tC - 1 1 - c h o l i n eP ET/CT has a relatively high
rate of false-negative results on a sextant basis. In addi-
tion it has been clearly shown that non-malignant pro-
static disorders may induce an increased
11C-choline
uptake [62]. Our model calculations are not dependent
on specificity as the irradiation of non-infiltrated voxels
does not influence TCP but this will lead to unessen-
tially big SIB target volumes.
Taken together, the relatively high efficacy rates of an
IMRT based SIB are potentially overestimating the real
benefit (Table 5, Table 6, Table 7 and Table 8, between
7.1% and 22.2%). Patient setup errors as well as intra-
f r a c t i o nm o t i o no ft h ep r o s t a t ew e r en o tc o n s i d e r e d
throughout the whole estimation process which could
potentially hamper the results in a negative way [63-67].
Another important factor influencing tumor control was
neglected in the model: the risk of regional, i.e. pelvic
nodal and/or systemic failure. This may be a potential
source of limiting the effectiveness of this approach as it
was assumed that local control entails biochemical con-
trol; in this regard a single cancer cell outside the pros-
tate could violate this assumption and diminish tumor
control.
Despite all of our considerations our model data are
not in contrast to data provided by Kim et al. [68]
claiming that selective boosting is more effective than
homogeneous dose escalation as sparing of normal tis-
sue is easier to achieve.
Furthermore, risk-adaptive optimization increases the
therapeutic ratio as compared to conventional selective
boosting IMRT. In another paper Kim et al. derive simi-
lar results, but mention the importance of the underly-
ing imaging modality and consecutively their sensitivity
in detecting occult tumor cells [69].
Utilizing an IMRT boost is an elegant technique but
one has to mention another classical but suitable
method: With brachytherapy the doses to the organs at
risk are lower or similar to IMRT-only. Dose escalation
for prostate tumors may also be easily achieved by bra-
chytherapy alone [70].
Conclusions
Regarding treatment planning in radiotherapy, choline
P E Tm a yo f f e rs o m ea d v a n t a g e si nt e r m so fs t a g i n g ,
tumor delineation and the description of biological pro-
cesses. However, a TCP-increase related to any IMRT
SIB on choline PET positive regions has to be consid-
ered as realistically low.
Additional file 1: This file contains a sheet where parameters like
choline PET sensitivity/specificity, a, a/b, g50, TCD50, dose, SIB dose and
single dose can be specified and a sheet carrying out all necessary
calculation steps.




RT: radiotherapy; IMRT: intensity-modulated radiotherapy; SIB: simultaneous
integrated boost; PTV: Planning target volume; LQ: linear-quadratic; TCP:
Table 8 TCP-increase for different sensitivities of PET, high whole prostate dose, different a/b values, calculated a and
low g50(CN + 2 definition)
a [Gy
-1] a/b [Gy] g50 Det. rate PET [%] Dose [Gy] SIB [Gy] Single dose [Gy] TCPconv [%] TCP Increase
[%]
0.03 1.5 1.4 81 78 90 2 84.5 9.1
0.03 1.5 1.4 64 78 90 2 84.5 7.1
0.04 3.1 1.4 81 78 90 2 84.5 8.5
0.04 3.1 1.4 64 78 90 2 84.5 6.6
0.06 8.3 1.4 81 78 90 2 84.5 7.7
0.06 8.3 1.4 64 78 90 2 84.5 6.0
Calculation of the TCP-increase after boosting choline PET positive regions within the prostate up to 90 Gy, low homogeneous dose 78 Gy. a/b was set to either
Fowler’s/Wang’s or Valdagni’s result, a was analytically determined in order to achieve agreement between calculated TCD50 and TCD50 obtained by Cheung et
al. g50 was again taken from Cheung’s data (CN + 2 definition).
Niyazi et al. Radiation Oncology 2010, 5:23
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Page 7 of 9tumor control probability; TCD50: tumor control dose 50%; PET: positron
emission tomography; SUV: standardized uptake value; CI: confidence
interval; SF: surviving fraction; EBRT: external beam radiotherapy; PSA:
prostate-specific antigen; ASTRO: American Society for Therapeutic Radiology
and Oncology; CN: current nadir; FWHM: full width at half maximum.
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